Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.

Publication Type:

Journal Article

Source:

The Journal of infectious diseases, Volume 203, Issue 1, p.117-21 (2011)

Keywords:

2011, Acyclovir, Adult, Amino Acid Substitution, Antiviral Agents, Botswana, Center-Authored Paper, Drug Resistance, Viral, Female, Herpes Genitalis, Herpesvirus 2, Human, HIV Infections, HIV Reverse Transcriptase, HIV-1, Humans, KENYA, Male, Middle Aged, Molecular Sequence Data, Mutation, Missense, Peru, Point Mutation, Prospective Studies, Selection, Genetic, Sequence Analysis, DNA, United States, Vaccine and Infectious Disease Division, Valine

Abstract:

Recent in vitro studies suggest that acyclovir may directly inhibit HIV-1 replication and can select for a specific HIV-1 reverse transcriptase mutation (V75I) with concomitant loss of an anti-HIV-1 effect. We tested for HIV-1 genotypic resistance at reverse transcriptase codon 75 in plasma from 168 HIV-1-infected persons from Botswana, Kenya, Peru, and the United States taking daily acyclovir or valacyclovir for between 8 weeks and 24 months. No V75I cases were detected (95% confidence interval, 0%-2.2%). These prospective in vivo studies suggest that standard-dose acyclovir or valacyclovir does not select for HIV-1 resistance.